Analyzing Inari Medical (NASDAQ:NARI) and Paradigm Medical Industries (OTCMKTS:PDMI)

Inari Medical (NASDAQ:NARI) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility and Risk

Inari Medical has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Paradigm Medical Industries has a beta of -0.45, indicating that its share price is 145% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Inari Medical and Paradigm Medical Industries, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inari Medical	0	2	5	0	2.71
Paradigm Medical Industries	0	0	0	0	N/A

Inari Medical currently has a consensus target price of $65.71, suggesting a potential upside of 30.93%.

Earnings and Valuation

This table compares Inari Medical and Paradigm Medical Industries’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inari Medical	$493.63 million	5.91	-$1.64 million	($0.41)	-122.41
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

Paradigm Medical Industries has lower revenue, but higher earnings than Inari Medical.

Institutional & Insider Ownership

91.0% of Inari Medical shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by company insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Inari Medical and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inari Medical	-4.54%	-1.65%	-1.23%
Paradigm Medical Industries	N/A	N/A	N/A

About Inari Medical

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.